| The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and … MJ Millan, A Gobert, F Lejeune, A Dekeyne, A Newman-Tancredi, ... Journal of Pharmacology and Experimental Therapeutics 306 (3), 954-964, 2003 | 740 | 2003 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and … MJ Millan, L Maiofiss, D Cussac, V Audinot, JA Boutin, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 791-804, 2002 | 550 | 2002 |
| Ras, Rap, and Rac Small GTP-binding Proteins Are Targets for Clostridium sordellii Lethal Toxin Glucosylation (∗) MR Popoff, E Chaves-Olarte, E Lemichez, C von Eichel-Streiber, ... Journal of Biological Chemistry 271 (17), 10217-10224, 1996 | 251 | 1996 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes A Newman-Tancredi, D Cussac, Y Quentric, M Touzard, L Verrièle, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 815-822, 2002 | 227 | 2002 |
| Agonist and antagonist actions of yohimbine as compared to fluparoxan at α2‐adrenergic receptors (AR)s, serotonin (5‐HT)1A, 5‐HT1B, 5‐HT1D and dopamine D2 and D … MJ Millan, A Newman‐Tancredi, V Audinot, D Cussac, F Lejeune, ... Synapse 35 (2), 79-95, 2000 | 223 | 2000 |
| Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D2-like receptor and … A Newman-Tancredi, D Cussac, V Audinot, JP Nicolas, F De Ceuninck, ... Journal of Pharmacology and Experimental Therapeutics 303 (2), 805-814, 2002 | 212 | 2002 |
| Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2‐adrenergic and serotonin2C receptors: a … MJ Millan, A Gobert, JM Rivet, A Adhumeau‐Auclair, D Cussac, ... European Journal of Neuroscience 12 (3), 1079-1095, 2000 | 210 | 2000 |
| Triptolide is an inhibitor of RNA polymerase I and II–dependent transcription leading predominantly to down-regulation of short-lived mRNA S Vispé, L DeVries, L Créancier, J Besse, S Bréand, DJ Hobson, ... Molecular cancer therapeutics 8 (10), 2780-2790, 2009 | 193 | 2009 |
| The GRB2 adaptor P Chardin, D Cussac, S Maignan, A Ducruix FEBS letters 369 (1), 47-51, 1995 | 190 | 1995 |
| S33084, a novel, potent, selective, and competitive antagonist at dopamine D3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218, 231 … MJ Millan, A Gobert, A Newman-Tancredi, F Lejeune, D Cussac, JM Rivet, ... Journal of Pharmacology and Experimental Therapeutics 293 (3), 1048-1062, 2000 | 154 | 2000 |
| Signal transduction and functional selectivity of F15599, a preferential post‐synaptic 5‐HT1A receptor agonist A Newman‐Tancredi, JC Martel, MB Assié, J Buritova, E Lauressergues, ... British journal of pharmacology 156 (2), 338-353, 2009 | 153 | 2009 |
| The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors MJ Millan, A Newman-Tancredi, Y Quentric, D Cussac Psychopharmacology 156, 58-62, 2001 | 142 | 2001 |
| Differential activation of Gq/11 and Gi3 proteins at 5-hydroxytryptamine2C receptors revealed by antibody capture assays: influence of receptor reserve and relationship to … D Cussac, A Newman-Tancredi, D Duqueyroix, V Pasteau, MJ Millan Molecular pharmacology 62 (3), 578-589, 2002 | 138 | 2002 |
| Binding of the Grb2 SH2 domain to phosphotyrosine motifs does not change the affinity of its SH3 domains for Sos proline‐rich motifs. D Cussac, M Frech, P Chardin The EMBO journal 13 (17), 4011-4021, 1994 | 138 | 1994 |
| Human dopamine D3 receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism D Cussac, A Newman-Tancredi, V Pasteau, MJ Millan Molecular pharmacology 56 (5), 1025-1030, 1999 | 134 | 1999 |
| Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety AL Auclair, JC Martel, MB Assié, L Bardin, P Heusler, D Cussac, M Marien, ... Neuropharmacology 70, 338-347, 2013 | 129 | 2013 |
| A Sos‐derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity D CUSSAC, M VIDAL, C LEPRINCE, WQ LIU, F CORNILLE, ... The FASEB journal 13 (1), 31-39, 1999 | 120 | 1999 |
| The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective … MJ Millan, L Seguin, A Gobert, D Cussac, M Brocco Psychopharmacology 174, 341-357, 2004 | 119 | 2004 |
| Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells D Cussac, E Boutet-Robinet, MC Ailhaud, A Newman-Tancredi, JC Martel, ... European journal of pharmacology 594 (1-3), 32-38, 2008 | 106 | 2008 |
| G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: a guanosine-5′-O-(3-[35S] thio)-triphosphate binding and antibody study A Newman-Tancredi, D Cussac, V Audinot, V Pasteau, S Gavaudan, ... Molecular pharmacology 55 (3), 564-574, 1999 | 104 | 1999 |